A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

European Journal of Cancer

Volumn 48, Issue 2, 2012, Pages 196-201

  Yi, Jun Ho ^a,d   Thongprasert, Sumitra ^b   Lee, Jeeyun ^a   Doval, D C ^c   Park, Se Hoon ^a   Park, Joon Oh ^a   Park, Young Suk ^a   Kang, Won Ki ^a   Lim, Ho Yeong ^a  

^a Sungkyunkwan University   (South Korea)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

^d Yonsei University College of Medicine   (South Korea)

Author keywords

Biliary tract cancer; Second line chemotherapy; Sunitinib

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; OXALIPLATIN; PLATINUM; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PATIENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE CONTROL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; WEAKNESS;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INDIA; INDOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES; REPUBLIC OF KOREA; SURVIVAL ANALYSIS; THAILAND;

EID: 84655161964     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.11.017     Document Type: Article

References (30)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. H.R. Shin, J.K. Oh, and E. Masuyer Epidemiology of cholangiocarcinoma: an update focusing on risk factors Cancer Sci 101 2010 579 585
3. G.D. Eslick Epidemiology of gallbladder cancer Gastroenterol Clin North Am 39 2010 307 330 ix
4. P.C. de Groen, G.J. Gores, N.F. LaRusso, L.L. Gunderson, and D.M. Nagorney Biliary tract cancers N Engl J Med 341 1999 1368 1378
5. J. Valle, H. Wasan, and D.H. Palmer Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer N Engl J Med 362 2010 1273 1281
6. Furuse.J. OT, and M.A. Miyazaki A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary cancer J Clin Oncol 27 2009 Abstr. 4579
7. A. Sharma, A.D. Dwary, and B.K. Mohanti Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study J Clin Oncol 28 2010 4581 4586
8. J. Lee, T.Y. Kim, and M.A. Lee Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas Cancer Chemother Pharmacol 61 2008 47 52 (Pubitemid 47512625)
9. J.W. Valle Advances in the treatment of metastatic or unresectable biliary tract cancer Ann Oncol 21 Suppl. 7 2010 vii345 vii348
10. Y. Hida, T. Morita, and M. Fujita Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas Anticancer Res 19 1999 2257 2260 (Pubitemid 29392531)
11. T. Nakashima, S. Kondoh, and H. Kitoh Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis Int J Mol Med 11 2003 33 39
12. C. Mobius, C. Demuth, and T. Aigner Evaluation of VEGF A expression and microvascular density as prognostic factors in extrahepatic cholangiocarcinoma Eur J Surg Oncol 33 2007 1025 1029 (Pubitemid 47408741)
13. A.X. Zhu, J.A. Meyerhardt, and L.S. Blaszkowsky Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study Lancet Oncol 11 2010 48 54
14. S.J. Lubner, M.R. Mahoney, and J.L. Kolesar Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study J Clin Oncol 28 2010 3491 3497
15. R.J. Motzer, T.E. Hutson, and P. Tomczak Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
16. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338 (Pubitemid 44528723)
17. E. Raymond, L. Dahan, and J.L. Raoul Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
18. H.J. Burstein, A.D. Elias, and H.S. Rugo Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 2008 1810 1816
19. M.A. Socinski, S. Novello, and J.R. Brahmer Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 2008 650 656 (Pubitemid 351264362)
20. L.B. Saltz, L.S. Rosen, and J.L. Marshall Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 2007 4793 4799 (Pubitemid 350086483)
21. M. Dror Michaelson, M.M. Regan, and W.K. Oh Phase II study of sunitinib in men with advanced prostate cancer Ann Oncol 20 2009 913 920
22. NCCN Clinical Practice Guidelines in Oncology: NCCN.org; 2011 Contract No.: Document Number.
23. S.Y. Oh, C.Y. Jeong, and S.C. Hong Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness Invest New Drugs 29 2011 1066 1072
24. T. Sasaki, H. Isayama, and Y. Nakai Feasibility study of gemcitabine, cisplatin combination chemotherapy for patients with refractory biliary tract cancer Invest New Drugs 2010
25. T. Sasaki, H. Isayama, and Y. Yashima S-1 monotherapy in patients with advanced biliary tract cancer Oncology 77 2009 71 74
26. T. Sasaki, H. Isayama, and Y. Nakai Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine Invest New Drugs 2010
27. P.A. Philip, M.R. Mahoney, and C. Allmer Phase II study of erlotinib in patients with advanced biliary cancer J Clin Oncol 24 2006 3069 3074 (Pubitemid 46638942)
28. C. Bengala, F. Bertolini, and N. Malavasi Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial Br J Cancer 102 2010 68 72
29. H. Uemura, N. Shinohara, and T. Yuasa A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety Jpn J Clin Oncol 40 2010 194 202
30. C. Yoo, J.E. Kim, and J.L. Lee The efficacy and safety of sunitinib in korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction Jpn J Clin Oncol 40 2010 980 985